Environmental, genetic, and molecular features of prostate cancer

被引:53
作者
Deutsch, E
Maggiorella, L
Eschwege, P
Bourhis, J
Soria, JC
Abdulkarim, B
机构
[1] Inst Gustave Roussy, UPRES, Lab EA 27 10, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Dept Radiat Therapy, F-94805 Villejuif, France
[3] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[4] Univ Paris 11, Dept Urol, Le Kremlin Bicetre, France
[5] Univ Alberta, Cross Canc Inst, Dept Radiat Oncol, Edmonton, AB, Canada
关键词
D O I
10.1016/S1470-2045(04)01468-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer is the sixth most common cancer in the world and the third leading cause of cancer in men. The increase in the understanding of prostate carcinogenesis over the past 15 years has helped to define crucial steps in the natural history of the disease, namely initiation and progression to androgen independence. This heterogeneous disease encompasses a range of environmental and familial factors, which provides strong support for the use of chemopreventive strategies. Most patients with advanced prostate cancer are treated with androgen-deprivation therapy, which leads to a striking regression of androgen-responsive cancer cells. A transition from an androgen-responsive to an androgen-unresponsive stage is seen during the clinical course in almost all patients with prostate cancer. This transition also signals a substantial worsening of prognosis. Here, we review the most important findings in prostate carcinogenesis and the molecular anomalies associated with the androgen-refractory stage.
引用
收藏
页码:303 / 313
页数:11
相关论文
共 87 条
[71]   Vitamin D and prostate cancer [J].
Tuohimaa, P ;
Lyakhovich, A ;
Aksenov, N ;
Pennanen, P ;
Syvälä, H ;
Lou, YR ;
Ahonen, M ;
Hasan, T ;
Pasanen, P ;
Bläuer, M ;
Manninen, T ;
Miettinen, S ;
Vilja, P ;
Ylikomi, T .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2001, 76 (1-5) :125-134
[72]   Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells [J].
Ueda, T ;
Mawji, NR ;
Bruchovsky, N ;
Sadar, MD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (41) :38087-38094
[73]  
VINCENT T, 2001, CANC PRINCIPLES PRAC
[74]   No association of germline alteration of MSR1 with prostate cancer risk [J].
Wang, L ;
McDonnell, SK ;
Cunningham, JM ;
Hebbring, S ;
Jacobsen, SJ ;
Cerhan, JR ;
Slager, SL ;
Blute, ML ;
Schaid, DJ ;
Thibodeau, SN .
NATURE GENETICS, 2003, 35 (02) :128-129
[75]  
Wang L, 2001, CANCER RES, V61, P6494
[76]  
Wang SI, 1998, CLIN CANCER RES, V4, P811
[77]   FAMILY HISTORY AND PROSTATE-CANCER RISK IN BLACK, WHITE, AND ASIAN MEN IN THE UNITED-STATES AND CANADA [J].
WHITTEMORE, AS ;
WU, AH ;
KOLONEL, LN ;
JOHN, EM ;
GALLAGHER, RP ;
HOWE, GR ;
WEST, DW ;
TEH, CZ ;
STAMEY, T .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 141 (08) :732-740
[78]   Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer [J].
Wilcox, G ;
Soh, S ;
Chakraborty, S ;
Scardino, PT ;
Wheeler, TM .
HUMAN PATHOLOGY, 1998, 29 (10) :1119-1123
[79]   Critical review of complementary therapies for prostate cancer [J].
Wilkinson, S ;
Chodak, GW .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2199-2210
[80]   New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents [J].
Williams, ED ;
Brooks, JD .
UROLOGY, 2001, 57 (4A) :100-102